BMS licenses Hengrui

China Outpaces US in Pharmaceutical R&D and Innovation

Bristol Myers Squibb paid Jiangsu Hengrui Pharmaceuticals $600 million upfront to license therapeutic molecules, highlighting China's shift from generic to novel drug innovation.